Technical note: linkage disequilibrium and disease-associated CTLA4 gene polymorphisms

J Immunol. 2001 Sep 1;167(5):2457-8. doi: 10.4049/jimmunol.167.5.2457.

Abstract

CTLA4 and CD28 are important regulators of T lymphocyte activation. Gene region 2q33 carrying genes for both CTLA4 and CD28 has been shown to be linked to many autoimmune diseases. Disease associations with particular CTLA4 gene polymorphisms have been reported. Recently, first lines of evidence emerged for functional effects of CTLA4 gene polymorphisms. Two independent studies reported a reduced inhibitory function of CTLA4 in individuals with certain CTLA4 genotypes: those with a high number of microsatellite repeats in one study and those with allele +49*G in exon 1 in the other one. We analyzed the strength of linkage disequilibrium between the three known CTLA4 polymorphisms among 577 independent chromosomes. Our results show that the polymorphisms previously suggested to be the functional risk factors nearly always occur together in a very frequent haplotype. Due to this strong linkage disequilibrium, we conclude that the previous reports studying merely a single polymorphism could not distinguish which variation actually caused the functional difference. Hence, either mutagenesis approaches or studies with data on all linked polymorphisms are still needed to determine the genuine functional risk polymorphism in this gene region.

MeSH terms

  • Abatacept
  • Alleles
  • Antigens, CD
  • Antigens, Differentiation / genetics*
  • Autoimmune Diseases / genetics*
  • Autoimmune Diseases / immunology*
  • CD28 Antigens / genetics
  • CTLA-4 Antigen
  • Celiac Disease / genetics
  • Celiac Disease / immunology
  • Chromosomes, Human, Pair 2 / genetics
  • Exons
  • Gene Frequency
  • Haplotypes
  • Humans
  • Immunoconjugates*
  • Linkage Disequilibrium*
  • Microsatellite Repeats
  • Polymorphism, Genetic*
  • Risk Factors

Substances

  • Antigens, CD
  • Antigens, Differentiation
  • CD28 Antigens
  • CTLA-4 Antigen
  • CTLA4 protein, human
  • Immunoconjugates
  • Abatacept